Mostrando 7 resultados de: 7
Subtipo de publicación
Article(7)
Evaluation of CIMAvaxEGF for the treatment of lung cancer: Meta-analysis of controlled clinical trials
ArticleAbstract: CIMAvaxEGF is a therapeutic cancer vaccine developed in Cuba and fully licensed in the country for uPalabras claves:EGF receptor, Epidermal growth factor, immunotherapy, Of non-small cell lung cancer vaccine therapy, Oncology vaccinesAutores:Aliuska Frías, Ballesteros J., Bárbara Wilkinson, Camilo Rodríguez, Carmen Elena Viada, Mabel Álvarez, Martha M. Fors-López, Neninger Vinageras E., Quintero J., Robaina M., Tania CrombetFuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusEvaluation of racotumomab for the treatment of lung cancer: Meta-analysis of controlled trials of the CIM
ArticleAbstract: Racotumomab is a therapeutic cancer vaccine entirely developed in Cuba and licensed in the country fPalabras claves:immunotherapy, Non-small cell lung cancer, Oncological vaccines, Racotumomab, Vaccinal treatmentAutores:Alfonso S., Aliuska Frías, Ballesteros J., Carmen Elena Viada, Hernández M., Mabel Álvarez, Macías A.E., Martha M. Fors-López, Quintero J., Robaina M.Fuentes:scopusNimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies
ArticleAbstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approvedPalabras claves:And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapiesAutores:Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania CrombetFuentes:scopusUnderlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer
ArticleAbstract: Background: Quality of Life Core Questionnaire of the European Organization for the Research and TrePalabras claves:Confirmatory factor analysis, EORTC QLQ-C30, Item response theory, quality of lifeAutores:Aliuska Frías, Ballesteros J., Bárbara Wilkinson, Bouza-Herrera C.N., Camilo Rodríguez, Carmen Elena Viada, García L., Mabel Álvarez, MARTHA FORS, Martha M. Fors-López, Tania CrombetFuentes:googlescopusQuality of life assessment as a pbkp_redictor of survival in cancer
ArticleAbstract: The quality of life and survival are variables to take into account in the clinical trial of oncologPalabras claves:clinical trials, Oncology, quality of life, SurvivalAutores:Aliuska Frías, Ballesteros J., Bouza-Herrera C.N., Carmen Elena Viada, García L., Mabel Álvarez, Martha M. Fors-López, Ramos M., Santiesteban Y.Fuentes:scopusSuperior efficacy and safety of a nonemulsive variant of the NGcGM3/VSSP vaccine in advanced breast cancer patients
ArticleAbstract: NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vacPalabras claves:Breast Cancer, NGcGM3/VSSP vaccine, SurvivalAutores:Arencibia M., Cabrera L., Carmen Elena Viada, Cepeda M., De La Torre A.V., Domecq M., Durán Y., Durrutí D., Fernandez L.E., Hernández J.J., Hernández L., Mabel Álvarez, Moreno Y.G., Pérez K., Ruiz R., Sánchez J.L., Sánchez L., Santiesteban E.R., Valls A.R., Vega A.M.Fuentes:scopus